XS
MRNA icon

XR Securities’s Moderna MRNA Stock Holding History

XR Securities’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,880
Closed -$200K – 295
2024
Q1 		$200K Buy
+1,880
New +$190K 0.01% 316
2023
Q4 		– Sell
-3,195
Closed -$269K – 420
2023
Q3 		$330K Buy
+3,195
New +$356K 0.03% 300
2023
Q1 		– Sell
-11,640
Closed -$1.92M – 511
2022
Q4 		$2.09M Buy
11,640
+6,328
+119% +$1.03M 0.2% 93
2022
Q3 		$628K Buy
5,312
+930
+21% +$141K 0.34% 63
2022
Q2 		$626K Buy
4,382
+449
+11% +$64.2K 0.21% 80
2022
Q1 		$677K Sell
3,933
-11,980
-75% -$2.02M 0.12% 52
2021
Q4 		$4.04M Buy
15,913
+6,820
+75% +$1.99M 0.39% 17
2021
Q3 		$3.5M Buy
9,093
+4,745
+109% +$1.75M 1.62% 10
2021
Q2 		$1.02M Sell
4,348
-4,930
-53% -$881K 0.45% 43
2021
Q1 		$1.22M Buy
9,278
+1,710
+23% +$248K 0.07% 38
2020
Q4 		$791K Buy
+7,568
New +$766K 0.05% 56

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

XR Securities's MRNA Position: Q2 2024 in Review

XR Securities sold out of Moderna (MRNA) in Q2 2024, closing a stake of 1,880 shares — an estimated $200K sold.

XR Securities first reported a position in MRNA in Q4 2020 and held it in 11 quarters. The position peaked at $4.04M in Q4 2021. 955 funds tracked by Wall St. Rank hold MRNA as of Q2 2024.

  • XR Securities reported no remaining Moderna position as of Q2 2024 after selling out during the quarter.
  • XR Securities sold 1,880 Moderna shares in Q2 2024, an estimated $200K.
  • XR Securities first reported a position in Moderna in Q4 2020 and held it in 11 quarters.
  • XR Securities's Moderna position peaked at $4.04M in Q4 2021.
  • 955 funds tracked by Wall St. Rank held Moderna as of Q2 2024.

Based on XR Securities's 13F filing for Q2 2024, filed 5 Aug 2024.